Latest News
Avita’s New Thailand Plant to Start Mass Production in March; A Strategic Weapon for Growth
2026-06-16

To mitigate the effects of the US-China trade war, Avita invested NT$300 million in a new production facility in Thailand, scheduled for mass production in March 2026. At full capacity, the plant is expected to effectively double the company's revenue.

Strategic Advantages:

  • Supply Chain Diversification: US-based "Customer B" plans to shift its fulfillment to the Thailand plant in 2026 to de-risk its supply chain. Avita is also actively courting large North American OEMs whose current suppliers lack manufacturing bases outside of China.
  • Tariff Resolution: The Thailand facility provides a "Plan B" for Japanese clients struggling with US tariffs on Chinese-made goods, with positive financial contributions expected to begin in 2027.
  • Financial Health: The NT$300 million investment is nearly fully contracted and will be paid in installments. The company reports a robust cash position and no further plans for large-scale capital expenditure or fundraising in the next two years.

Chairman Chuang Ming-hui emphasized that with inventory digestion complete and a "third-country" production advantage, Avita has exited its operational slump, targeting simultaneous growth in revenue and profit while maintaining gross margins above 30%.

Resource: 豪展泰國新廠明年3月量產,營運成長添利器

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2026 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:9F., No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City , Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978